Clinical Trials Logo

Melanosis clinical trials

View clinical trials related to Melanosis.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 2

NCT ID: NCT03472235 Not yet recruiting - Melasma Clinical Trials

Microneedle and Trichloroaceticacid in Treatment of Melasma

Start date: April 5, 2018
Phase: N/A
Study type: Interventional

Melasma is an acquired disorder of hyperpigmentation characterised by blotchy, light-to-dark brown macules distributed symmetrically on the sun-exposed parts of the body. Although many factors have been proposed to have a role in pathogenesis, the exact ethology is yet to be understood. The most commonly identifiable risk factors include ultraviolet radiation, genetic predisposition, pregnancy, oral contraceptives, thyroid disease and drugs like antiepileptic. The excessive pigmentation has been attributed to both melanocytosis (increased number of melanocytes) as well as melano genesis (excess production of melanin) as confirmed in a histopathological study on Asian patients.] Furthermore, a vascular component has also been proposed to play a role in the pathogenesis of melisma. Kim et al. have found that lesion melasma skin had greater expression of the vascular endothelial growth factor in keratinocytes compared to nearby nonlesional skin.

NCT ID: NCT03153852 Not yet recruiting - Melasma Clinical Trials

Modified Jessner's Solution With Trichloroacetic Acid Versus Glycolic Acid With Trichloroacetic Acid

Start date: March 15, 2018
Phase: Phase 4
Study type: Interventional

Melasma is a common acquired disorder of hyperpigmentation characterized by irregular light brown to dark brown patches of hyperpigmentation commonly affecting the face. The trunk and arms are also occasionally involved .

NCT ID: NCT03008655 Not yet recruiting - Melasma Clinical Trials

1064-nm Q-switched Nd:YAG Laser and Intradermal Tranexamic Acid for Melasma

Start date: January 2017
Phase: N/A
Study type: Interventional

BACKGROUND: Melasma is a chronic, often relapsing skin disorder, with poor long-term results from all current therapies.Q switched 1064nm Nd:YAG laser and intradermal tranexamic acid both showed efficacy on the treatment of melasma. However, no combination therapy of both be reported. OBJECTIVES: To compare the efficacy of low influence Q switched 1064nm Nd:YAG laser and low influence Q switched 1064nm Nd:YAG laser combined with intradermal tranexamic acid injection for melasma.